Immunotherapy in pituitary carcinomas and aggressive pituitary tumors

G Raverot, MD Ilie - Best Practice & Research Clinical Endocrinology & …, 2022 - Elsevier
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …
被引用次数：14 相关文章

[引用][C] Immunotherapy in pituitary carcinomas and aggressive pituitary tumors

G Raverot, MD Ilie - Best Practice and Research: Clinical …, 2022 - cnrs.hal.science
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors - CNRS - Centre
national de la recherche scientifique Accéder directement au contenu Documentation FR …

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.

G Raverot, MD Ilie - … Practice & research. Clinical Endocrinology & …, 2022 - europepmc.org
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors

G Raverot, MD Ilie - Best practice & research. Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …